Back to all webinars
Lymphoma management during the COVID-19 pandemic: New evidence-based insights and recommendations
Christian Buske, Wojciech Jurczak and Meletios Dimopoulos cover the key challenges in managing B-cell malignancies during the COVID-19 pandemic, including new evidence-based insights and recommendations for treating aggressive and indolent lymphomas and managing COVID-19 vaccinations.
Speakers
Hematologic malignancies and COVID-19: The key challenges
Fast-forward to:
Risk of COVID-19 to patients with cancer
61727f669ff4cc05890bb8f4
Severity and mortality of COVID-19 in patients with cancer and the impact of treatment status
61af6e8ff8742a0daf9e3577
Anti-CD20 therapy and COVID-19 outcomes
61af7056f8742a0daf9e358d
SARS-CoV-2 vaccinations in patients with B-cell malignancies
61af715f2fc9050db56f8877
Recommendations - Indolent lymphoma
No entries
Recommendations - Aggressive lymphoma
No entries
Panel discussion
No entries
Audience Q&A
Fast-forward to:
Should patients with lymphoma and no response to two doses of SARS-CoV-2 vaccine receive a third vaccine dose?
61af63481b44ef0dbc708d01
How important is the cellular response to COVID-19 infection or vaccination in patients with lymphoma?
61af64ba2fc9050db56f8762
Do you recommend SARS-CoV-2 vaccination during treatment?
61af66403ebc500dae6c93c8
Is the time of recovery from COVID-19 longer and do you see more “long COVID-19” in patients with lymphoma or leukemia?
61af66e91b44ef0dbc708d1e
What has been your experience of tele-medicine and could it be used more often after COVID-19?
61af78fbf8742a0daf9e365d
How do you manage patients being treated with ibrutinib during the COVID-19 pandemic?
61af79ad3ebc500dae6c9583